|Bid||356.60 x 1200|
|Ask||356.90 x 1200|
|Day's range||352.57 - 370.80|
|52-week range||58.81 - 464.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||19.50|
|Earnings date||09 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||334.31|
Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision.
Shares of coronavirus stocks Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX) rose on Thursday by 1.4% and 4.9%, respectively, in contrast to the stock market's dip on the day. This followed news that the two companies had their coronavirus vaccines fully approved by a national regulator. On Thursday morning, it switched on the green light for both Moderna's mRNA-1273 (brand-named SpikeVax) and Comirnaty from BioNTech and its development partner Pfizer (NYSE: PFE).
Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose.